Admiraal De Ruyter Ziekenhuis B.V.
- Address
- 'S-Gravenpolderseweg 114, 4462 RA Goes, The Netherlands
Admiraal De Ruyter Ziekenhuis B.V. - Comprehensive Clinical Research Center
Admiraal De Ruyter Ziekenhuis B.V. is a distinguished clinical research institution with extensive expertise across multiple therapeutic domains. The center demonstrates particular strength in oncology research, with a robust portfolio spanning breast cancer, colorectal cancer, hematologic malignancies, and gastrointestinal cancers. Their research encompasses advanced treatment strategies including targeted therapies, immunotherapy combinations, and precision medicine approaches for both solid tumors and blood cancers.
- Advanced breast cancer therapeutics, including hormone receptor-positive disease, triple-negative breast cancer, and HER2-positive malignancies with novel combination strategies
- Cardiovascular disease management, focusing on heart failure with reduced ejection fraction, atrial fibrillation, and cardioprotective strategies in cancer treatment
- Hematologic malignancies including lymphomas (Hodgkin, mantle cell, diffuse large B-cell) and acute myeloid leukemia with innovative targeted agents
- Gastrointestinal oncology, endocrine disorders, and metabolic conditions including obesity-related cardiovascular complications
Beyond oncology, the center actively investigates diverse conditions including rheumatoid arthritis with personalized treatment approaches, hypothyroidism with combination hormone therapy, contraceptive efficacy studies, and ophthalmologic conditions such as progressive myopia. The institution's commitment to personalized medicine is evident through biomarker-driven trials and genetic stratification strategies, while maintaining focus on improving patient quality of life, reducing treatment-related toxicity, and establishing cost-effective therapeutic approaches across multiple disease states.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 106 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 106 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Admiraal De Ruyter Ziekenhuis B.V.
lock Showing 1 of 38 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 106 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Oxaliplatin | 6 | Unknown | 2019-07-01 | 2026-03-11 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.